Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
5 Things to Know Before the Stock Market Opens
08:00am, Tuesday, 22'nd Jul 2025
Stock futures are little changed as investors watch for more earnings and trade developments; AstraZeneca (AZN) said it plans to invest $50 billion in U.S. production facilities; Opendoor Technologies
AstraZeneca Plans to Invest $50B in US Manufacturing and Research by 2030
07:20am, Tuesday, 22'nd Jul 2025
AstraZeneca (AZN) said Tuesday it's planning to invest $50 billion in expanding its manufacturing and research presence in the U.S. by 2030, as worries about President Donald Trump's tariffs loom over
AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans
04:22am, Tuesday, 22'nd Jul 2025
AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is announ
AstraZeneca commits $50B to US expansion amid Trump tariff pressure
04:20am, Tuesday, 22'nd Jul 2025
AstraZeneca on Monday announced plans to invest $50 billion in its US operations by 2030, a sweeping commitment that includes building its largest-ever manufacturing facility in Virginia and expanding
AstraZeneca announces $50bn US investment in manufacturing and R&D
03:31am, Tuesday, 22'nd Jul 2025
AstraZeneca PLC (LSE:AZN) has unveiled plans to invest $50 billion in the United States by 2030, marking its largest-ever commitment to a single country and signalling a major boost for domestic drug
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
03:01am, Tuesday, 22'nd Jul 2025
AstraZeneca has become the latest pharma firm to announce a multi-billion investment in the U.S. The Anglo-Swedish biotech firm has committed to spend $50 billion by 2030.
AstraZeneca to invest $50B in US economy by 2030
06:15pm, Monday, 21'st Jul 2025
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.
AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D
05:35pm, Monday, 21'st Jul 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
05:32pm, Monday, 21'st Jul 2025
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to Presi
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
07:16pm, Thursday, 17'th Jul 2025
Astrazeneca (AZN) closed the most recent trading day at $69.26, moving 1.17% from the previous trading session.
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
02:10pm, Thursday, 17'th Jul 2025
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
AstraZeneca shares open lower after rare disease drug fails to meet main trial goal
03:31am, Wednesday, 16'th Jul 2025
AstraZeneca PLC (LSE:AZN) shares opened lower on Wednesday after a late-stage trial of its experimental treatment for AL amyloidosis failed to meet its primary target in the overall patient group. The
AstraZeneca drug fails main goal of late-stage amyloidosis study
02:19am, Wednesday, 16'th Jul 2025
AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of pro
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
10:45am, Tuesday, 15'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca Meets All Key Goals in Phase III Hypertension Study
09:36am, Tuesday, 15'th Jul 2025
AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.
